Abivax (AAVXF) Liabilities and Shareholders Equity (2021 - 2025)

Abivax has reported Liabilities and Shareholders Equity over the past 5 years, most recently at $680.2 million for Q4 2025.

  • Quarterly results put Liabilities and Shareholders Equity at $680.2 million for Q4 2025, up 210.16% from a year ago — trailing twelve months through Dec 2025 was $1.3 billion (up 71.81% YoY), and the annual figure for FY2025 was $660.2 million, up 197.21%.
  • Liabilities and Shareholders Equity for Q4 2025 was $680.2 million at Abivax, up from $219.3 million in the prior quarter.
  • Over the last five years, Liabilities and Shareholders Equity for AAVXF hit a ceiling of $680.2 million in Q4 2025 and a floor of $77.1 million in Q4 2022.
  • Median Liabilities and Shareholders Equity over the past 5 years was $219.3 million (2024), compared with a mean of $290.7 million.
  • Biggest five-year swings in Liabilities and Shareholders Equity: crashed 38.32% in 2022 and later skyrocketed 356.58% in 2023.
  • Abivax's Liabilities and Shareholders Equity stood at $125.0 million in 2021, then crashed by 38.32% to $77.1 million in 2022, then skyrocketed by 356.58% to $351.9 million in 2023, then plummeted by 37.68% to $219.3 million in 2024, then skyrocketed by 210.16% to $680.2 million in 2025.
  • The last three reported values for Liabilities and Shareholders Equity were $680.2 million (Q4 2025), $219.3 million (Q4 2024), and $351.9 million (Q4 2023) per Business Quant data.